Biohaven Ltd. (BHVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $2.09B
Last updated: Nov 17, 2026 at 11:04 AM ET
Biohaven Ltd. (BHVN) Stock Forecast
Analysts expect Biohaven (BHVN) to earn -$1.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $143.33M. Of 17 analysts, 12 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.24, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 17.6% |
| Buy | 9 | 52.9% |
| Hold | 4 | 23.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.9% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 27.5%.
- Fiscal year ending Dec 31, 2026
- -$1.39
- EPS consensus, revenue $143.33M
- Fiscal year ending Dec 31, 2027
- -$1.53
- EPS consensus, revenue $103.89M
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.39 | -$2.85 to -$0.06 | 6 | $143.33M | N/A | 15 |
| Dec 31, 2027 | -$1.53 | -$2.07 to -$0.62 | 6 | $103.89M | N/A | 16 |
Quarterly Estimates
The EPS consensus falls from -$0.20 for the quarter ending Dec 31, 2026 to -$0.46 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.83 to $2.07 | 19 | $43.86M | N/A | 14 |
| Mar 31, 2027 | -$0.46 | -$0.46 to -$0.46 | 1 | $60.05M | N/A | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.39 | -$1.30 | -$1.65 | -$1.97 | -$2.41 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.53 | -$1.74 | -$1.87 | -$1.94 | -$1.94 | N/A |
| Quarter ending Mar 31, 2027 | -$0.46 | -$0.46 | -$0.51 | -$0.51 | -$0.53 | N/A |
Frequently Asked Questions About BHVN
What is the BHVN stock forecast?
Consensus analyst estimates put Biohaven's EPS at -$1.39 for the fiscal year ending Dec 31, 2026, on revenue of $143.33M. The consensus rating from 17 analysts is Buy.
How do analysts rate BHVN stock?
Of 17 analysts covering Biohaven, 3 rate it Strong Buy, 9 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BHVN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.39, with estimates from -$2.85 to -$0.06 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.53, with estimates from -$2.07 to -$0.62 from 6 analysts.
What revenue do analysts expect from Biohaven next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $143.33M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $103.89M.
How many analysts cover BHVN?
17 analysts rate Biohaven stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BHVN pages: Overview, Earnings, Forecast, Financials, Competitors